ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) insider Eric Karas sold 15,000 shares of the firm's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $16.99, for a total value of $254,850.00. Following the transaction, the insider owned 10,315 shares in the company, valued at approximately $175,251.85. The trade was a 59.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Eric Karas also recently made the following trade(s):
- On Wednesday, June 18th, Eric Karas sold 15,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $16.00, for a total value of $240,000.00.
ARS Pharmaceuticals Price Performance
Shares of SPRY traded down $0.27 during trading hours on Friday, reaching $16.49. 881,491 shares of the stock traded hands, compared to its average volume of 1,343,652. ARS Pharmaceuticals, Inc. has a 52-week low of $8.91 and a 52-week high of $18.90. The company has a current ratio of 11.00, a quick ratio of 10.74 and a debt-to-equity ratio of 0.30. The company has a market cap of $1.62 billion, a P/E ratio of -103.02 and a beta of 0.90. The company's 50-day moving average price is $14.85 and its two-hundred day moving average price is $13.20.
ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, hitting analysts' consensus estimates of ($0.35). ARS Pharmaceuticals had a negative return on equity of 6.94% and a negative net margin of 16.11%. The company had revenue of $7.97 million for the quarter, compared to analysts' expectations of $7.48 million. On average, analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen raised ARS Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, June 28th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, ARS Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $31.00.
Get Our Latest Analysis on SPRY
Institutional Investors Weigh In On ARS Pharmaceuticals
Several large investors have recently bought and sold shares of SPRY. Alliancebernstein L.P. lifted its holdings in shares of ARS Pharmaceuticals by 1.1% in the 1st quarter. Alliancebernstein L.P. now owns 3,922,805 shares of the company's stock valued at $49,349,000 after acquiring an additional 42,071 shares during the last quarter. Vanguard Group Inc. raised its position in ARS Pharmaceuticals by 0.7% during the first quarter. Vanguard Group Inc. now owns 3,488,293 shares of the company's stock valued at $43,883,000 after purchasing an additional 23,341 shares during the period. Cormorant Asset Management LP lifted its stake in shares of ARS Pharmaceuticals by 220.0% in the 1st quarter. Cormorant Asset Management LP now owns 1,600,000 shares of the company's stock valued at $20,128,000 after purchasing an additional 1,100,000 shares during the last quarter. MPM Bioimpact LLC bought a new stake in shares of ARS Pharmaceuticals in the 1st quarter valued at approximately $16,519,000. Finally, Alyeska Investment Group L.P. boosted its holdings in shares of ARS Pharmaceuticals by 903.0% in the 4th quarter. Alyeska Investment Group L.P. now owns 1,253,724 shares of the company's stock worth $13,227,000 after purchasing an additional 1,128,724 shares during the period. Institutional investors own 68.16% of the company's stock.
About ARS Pharmaceuticals
(
Get Free Report)
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
See Also

Before you consider ARS Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ARS Pharmaceuticals wasn't on the list.
While ARS Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.